- Home
- CNF vs NRSN Comparison
CNF vs NRSN Comparison
Compare CNF & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNF
- NRSN
- Stock Information
- Founded
- CNF 1999
- NRSN 2017
- Country
- CNF China
- NRSN Israel
- Employees
- CNF N/A
- NRSN N/A
- Industry
- CNF Finance: Consumer Services
- NRSN Biotechnology: Pharmaceutical Preparations
- Sector
- CNF Finance
- NRSN Health Care
- Exchange
- CNF Nasdaq
- NRSN Nasdaq
- Market Cap
- CNF 35.7M
- NRSN 31.1M
- IPO Year
- CNF 2018
- NRSN 2021
- Fundamental
- Price
- CNF $4.27
- NRSN $1.15
- Analyst Decision
- CNF
- NRSN Buy
- Analyst Count
- CNF 0
- NRSN 2
- Target Price
- CNF N/A
- NRSN $14.00
- AVG Volume (30 Days)
- CNF 63.1K
- NRSN 1.3M
- Earning Date
- CNF 08-28-2025
- NRSN 09-17-2025
- Dividend Yield
- CNF N/A
- NRSN N/A
- EPS Growth
- CNF N/A
- NRSN N/A
- EPS
- CNF N/A
- NRSN N/A
- Revenue
- CNF $50,241,013.00
- NRSN N/A
- Revenue This Year
- CNF $252.34
- NRSN N/A
- Revenue Next Year
- CNF N/A
- NRSN N/A
- P/E Ratio
- CNF N/A
- NRSN N/A
- Revenue Growth
- CNF N/A
- NRSN N/A
- 52 Week Low
- CNF $2.36
- NRSN $0.80
- 52 Week High
- CNF $20.00
- NRSN $2.60
- Technical
- Relative Strength Index (RSI)
- CNF 52.57
- NRSN 40.37
- Support Level
- CNF $2.85
- NRSN $1.12
- Resistance Level
- CNF $4.26
- NRSN $1.26
- Average True Range (ATR)
- CNF 0.47
- NRSN 0.07
- MACD
- CNF -0.05
- NRSN 0.01
- Stochastic Oscillator
- CNF 64.07
- NRSN 16.73
About CNF CNFinance Holdings Limited each representing twenty (20)
CNFinance Holdings Ltd is an equity loan service provider. It focuses on the development of small and micro-enterprises. It generates revenue in the form of interest and financing service fees on loans and interest on deposits with banks. Its primary target borrower segment is MSE owners who own real properties in Tier 1 and Tier 2 cities in China. Geographically, it has an operation in PRC.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.